Duality Advisers LP Invests $1.86 Million in Myriad Genetics, Inc. (NASDAQ:MYGN)

Duality Advisers LP bought a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 163,717 shares of the company’s stock, valued at approximately $1,857,000. Duality Advisers LP owned 0.22% of Myriad Genetics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc boosted its position in shares of Myriad Genetics by 135.3% in the first quarter. Versant Capital Management Inc now owns 1,793 shares of the company’s stock worth $25,000 after buying an additional 1,031 shares during the period. Joseph P. Lucia & Associates LLC purchased a new stake in shares of Myriad Genetics in the first quarter worth about $29,000. Fifth Third Bancorp acquired a new position in shares of Myriad Genetics in the first quarter worth about $47,000. Advisor Group Inc. lifted its stake in shares of Myriad Genetics by 16.0% in the fourth quarter. Advisor Group Inc. now owns 3,929 shares of the company’s stock worth $108,000 after acquiring an additional 542 shares in the last quarter. Finally, First Bank & Trust lifted its stake in shares of Myriad Genetics by 80.3% in the first quarter. First Bank & Trust now owns 3,932 shares of the company’s stock worth $56,000 after acquiring an additional 1,751 shares in the last quarter. 98.96% of the stock is owned by institutional investors.

Shares of MYGN opened at $12.07 on Friday. Myriad Genetics, Inc. has a 1 year low of $9.24 and a 1 year high of $48.40. The company has a market cap of $899.88 million, a price-to-earnings ratio of -6.04, a price-to-earnings-growth ratio of 9.93 and a beta of 1.28. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.87 and a current ratio of 3.14. The firm has a fifty day moving average of $11.92 and a 200-day moving average of $16.51.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.10). Myriad Genetics had a negative net margin of 19.49% and a positive return on equity of 1.95%. The company had revenue of $164.00 million for the quarter, compared to the consensus estimate of $167.38 million. During the same quarter in the prior year, the firm earned $0.46 earnings per share. Myriad Genetics’s revenue for the quarter was down 24.4% compared to the same quarter last year. Analysts predict that Myriad Genetics, Inc. will post -0.64 EPS for the current year.

MYGN has been the topic of several recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Myriad Genetics in a research note on Wednesday, May 6th. Piper Sandler cut their price target on Myriad Genetics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. JPMorgan Chase & Co. cut their price target on Myriad Genetics from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Wednesday, May 6th. Finally, BidaskClub cut Myriad Genetics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 27th. Four research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $20.56.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Story: What Are Cryptocurrencies?

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.